Eli Lilly has added $1 billion to its investment plan for a new manufacturing facility in Ireland that will be used to produce its Alzheimer's therapy donanemab.
The life sciences industry is currently undergoing a significant transformation, driven by the rapid development of new modalities such as cell and gene therapies (CAGT), and substantial ne
CordenPharma has launched a €900 million ($981 million) investment programme to prepare for an expected surge in demand for peptide production capacity – driven by GLP-1 receptor agonists.
Novo Nordisk has gone up another gear in its drive to boost manufacturing capacity for its fast-growing GLP-1 agonist drugs, announcing plans to build a $4.1 billion fill-and-finish facilit
AstraZeneca is backing up its considerable investment in antibody-drug conjugates (ADCs) for cancer with the construction of a $1.5 billion new facility in Singapore to ma
This week, pharmaphorum heads to the Big Apple for the FT US Pharma and Biotech Summit, a one-day event where executives from some of the world’s top pharma companies will come together to
AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure FDA approval – although the jury is out on that.
The Life Sciences Generative AI Council aims to bring together the best minds in pharma, academia, and technology to advance the use of GenAI in life sciences R&D, seeking through pinpo